The month of November is Lung Cancer Awareness Month, and staggering statistics show it's the number one cancer killer in the ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

Australian cancer ... help. Patient groups and experts are calling on Health Minister Mark Butler to intervene and overrule ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

If you have non-small cell lung cancer (NSCLC), your doctor will recommend PD-L1 testing. This test will help your doctor understand if you ... which include the following medications: pembrolizumab ...

Only some lung cancer patients benefit ... So, immunotherapy drugs help a patient’s immune system control their cancer on its own before it can spread. Unfortunately, immunotherapy does not work for ...